United Therapeutics Corporation
NASDAQ:UTHRBiotechnology
-$18.01 today
- Market cap
- $24.59B
- Beta
- 0.57
- P/E (TTM)
- 18.0
- EPS (TTM)
- $29.60
Volume 0.42M
Average 0.52M
UTHR Deferred Revenue (Non-current)
Payments received for goods or services the company will deliver after more than one year.
United Therapeutics CorporationNASDAQ: UTHR
Deferred Revenue (Non-current) · Q2 FY2026 · quarter ended Jun 2026
Deferred revenue (non-current) remains negative
Q2 FY2026 deferred revenue (non-current) was $0, compared with $0 a year earlier.
Context
- Deferred revenue (non-current) amounted to 0.0% of total assets at the end of Q2 FY2026, unchanged from a year earlier.
- Deferred revenue (non-current) increased in 0 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Deferred Revenue (Non-current) history
USD · from the balance sheet
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Deferred Revenue (Non-current) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Deferred Revenue (Non-current) vs competitors
How UTHR compares with its peers on the latest reported figures
- UTHR's Jun 2026 deferred revenue (non-current) of $0 is the highest of the 5 companies compared; the peer median is $0.
- Deferred revenue (non-current) amounts to 0.0% of total assets for UTHR, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $0 | — | — | 0.0% | |
| Jun 2026 | $0 | — | — | 0.0% | |
| Jun 2026 | $0 | — | — | 0.0% | |
| Sep 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding UTHR) | $0 | — | — | 0.0% | |
Competitors are the stored peer set for UTHR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 894.8M | 961.2M | 1.21B | 1.7B | 1.56B |
| Short-term Investments | 1.04B | 1.88B | 1.79B | 1.57B | 0 |
| Net Receivables | 198.7M | 220.4M | 278.9M | 279.3M | 350.2M |
| Inventory | 93.8M | 102M | 111.8M | 157.9M | 183.1M |
| Other Current Assets | 100.4M | 219.2M | 166.2M | 169.7M | 1.61B |
| Total Current Assets | 2.32B | 3.38B | 3.55B | 3.87B | 3.7B |
| Property, Plant & Equipment (Net) | 780.9M | 861.5M | 1.05B | 1.22B | 1.73B |
| Goodwill | 28M | 28M | 33.7M | 32.3M | 0 |
| Intangible Assets | 16.6M | 16.5M | 80.5M | 79.6M | 116.5M |
| Long-term Investments | 1.65B | 1.32B | 1.91B | 1.48B | 1.78B |
| Tax Assets | 261.9M | 327.7M | 394.8M | 458.4M | 357.7M |
| Other Non-current Assets | 108.2M | 114.3M | 151.8M | 222.1M | 196.9M |
| Total Non-current Assets | 2.85B | 2.66B | 3.62B | 3.49B | 4.18B |
| Total Assets | 5.17B | 6.04B | 7.17B | 7.36B | 7.88B |
| Account Payables | 3.8M | 4.1M | 5.6M | 6M | 7.1M |
| Short-term Debt | 0 | 0 | 400M | 300M | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 248M | 13M | 40.5M | 432.1M | 39.3M |
| Total Current Liabilities | 305.4M | 343.2M | 804.4M | 738.1M | 560.6M |
| Long-term Debt | 800M | 800M | 300M | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 104.8M | 104.6M | 77.8M | 181.9M | 192.9M |
| Total Non-current Liabilities | 904.8M | 904.6M | 377.8M | 181.9M | 223.2M |
| Total Liabilities | 1.21B | 1.25B | 1.18B | 920M | 783.8M |
| Common Stock | 700K | 700K | 700K | 800K | 800K |
| Retained Earnings | 4.32B | 5.04B | 6.03B | 7.22B | 8.56B |
| Accumulated OCI | (23M) | (55.5M) | (12.8M) | (3.4M) | 900K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 3.96B | 4.8B | 5.98B | 6.44B | 7.1B |
| Total Debt | 800M | 800M | 700M | 300M | 37.6M |
| Net Debt | (94.8M) | (161.2M) | (507.7M) | (1.4B) | (1.52B) |
United Therapeutics Corporation
NASDAQ:UTHR
Intrinsic Alpha fair value
Locked
Current Price
$577.34
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.